Pfizer Japan, Inc. received manufacturing and marketing authorization for Champix Tablet 0.5 mg/1mg (varenicline tartrate), a smoking cessation aid for nicotine-dependent  smokers.     Champix, Japan’s first oral smoking cessation treatment, brings about a smoking cessation effect as a non-nicotine partial agonist1 that binds to a4b2 nicotine receptors in the brain, relieving withdrawal symptoms and tobacco craving associated with smoking. If a person smokes a cigarette while receiving treat...